Journal Mobile Options
Table of Contents
Vol. 58, No. 1, 2012
Issue release date: December 2011

Effect of Vitamin E Administration on the Elevated Oxygen Stress and the Telomeric and Subtelomeric Status in Alzheimer’s Disease

Guan J.-Z. · Guan W.-P. · Maeda T. · Makino N.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Oxidative stress (OS) may be involved in the neurodegenerative process in Alzheimer’s disease (AD). Telomeres, the repeated sequences that cap chromosome ends, undergo shortening with each cell division, are sensitive to OS, and serve as markers of a cell’s replicative history. Telomere length shortening has been reported to relate to OS with aging process and aging-associated diseases, but the telomeric changes were not always identical, especially in change of telomere length distribution and subtelomeric methylation. The involvement of an OS-associated telomere change in the pathogenesis of AD has been discussed for decades, and the telomere length and telomerase activity were analyzed. However, other telomeric factors, such as the telomere distribution and subtelomeric methylation status, have not yet been analyzed. Objective: The subtelomeric methylation status as well as the telomere length were studied in AD with an antioxidant vitamin in terms of OS. Methods: We measured urinary 8-iso-PGF2α, a lipid-peroxidation product as an OS marker, and methylated and non-methylated telomere lengths in the peripheral blood mononuclear cells by Southern blotting in AD patients before and after vitamin E treatment. Results: The level of urinary 8-iso-PGF2α was found to have increased in AD. Middle-ranged telomeres (4.4–9.4 kb) increased and the shortest telomeres (<4.4 kb) decreased in AD patients. Telomeres were more methylated in both long telomeres and in short telomeres in AD compared with the control. The oral administration of the antioxidant vitamin E in 400 mg/day for 6 months in AD patients partly reversed AD-associated alterations in OS marker levels. Conclusions: AD patients showed an elevated OS marker level, and vitamin E lowered the OS level. In comparison with controls, AD patients showed shorter telomere lengths. Cells with short and long telomeres bore relatively hypermethylated subtelomeres in AD patients. Aging-associated accumulation of cells bearing short telomeres was not observed in AD. These results imply that long telomeres with hypomethylation tend to shorten faster, and cells bearing short telomeres with hypomethylation tend to more easily enter into a senescent state under elevated OS stress in AD. However, no significant effect on the altered telomeric profiles in AD patients could be detected after a 6-month administration of vitamin E.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Fearnley JM, Lees AJ: Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 1991;114:2283–2301.
  2. Roberts LJ II, Montine TJ, Markesbery WR, Tapper AR, Hardy P, Chemtob S, Dettbarn WD, Morrow JD: Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 1998;273:13605–13612.
  3. Pratico D, Lee VM-Y, Trojanowski JQ, Rokach J, Fitzgerald GA: Increased F2-isoprostanes in Alzheimer’s disease: evidence for enhanced lipid peroxidation in vivo. FASEB 1998;12:1777–1783.
  4. Montine TJ, Beal MF, Cudkowicz ME, O’Donnell H, Margolin RA, McFarland L, Bachrach AF, Zackert WE, Roberts LJ, Morrow JD: Increased CSF F2-isoprostane concentration in probable AD. Neurology 1999;52:562–565.
  5. von Zglinicki T: Oxidative stress shortens telomeres. Trends Biochem Sci 2002;27:339–344.
  6. Pratico D: F(2)-isoprostanes: sensitive and specific non-invasive indices of lipid peroxidation in vivo. Atherosclerosis 1999;147:1–10.
  7. Epel ES, Blackburn EH, Lin F, Dhabhar FS, Adler NE, Morrow JD, Cawthon RM: Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci USA 2004;101:17312–17315.
  8. Blackburn EH: Structure and function of telomeres. Nature 1991;350:569–573.
  9. Zakian VA: Telomeres: beginning to understand the end. Science 1995;270:1601–1607.
  10. Harley CB, Futcher AB, Greider CW: Telomeres shorten during ageing of human fibroblasts. Nature 1990;345:458–460.
  11. Allsopp RC, Vaziri H, Patterson C, Goldstein S, Younglai EV, Futcher AB, Greider CW, Harley CB: Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci USA 1992;89:10114–10118.
  12. Brouilette S, Singh RK, Thompson JR, Goodall AH, Samani NJ: White cell telomere length and risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol 2003;23:842–846.
  13. Ogami M, Ikura Y, Ohsawa M, Goldstein S, Younglai EV, Futcher AB, Greider CW, Harley CB: Telomere shortening in human coronary artery diseases. Arterioscler Thromb Vasc Biol 2004;24:546–550.
  14. Friedrich U, Gries E, Schwab M, Fritz P, Thon K, Klotz U: Telomere length in different tissues of elderly patients. Mech Ageing 2000;119:89–99.
  15. Frenck RW Jr, Blackburn EH, Shannon KM: The rate of telomere sequence loss in human leukocytes varies with age. Proc Natl Acad Sci USA 1998;95:5607–5610.
  16. McGeer EG, Yasojima K, Schwab C, McGeer PL: The pentraxins: possible role in Alzheimer’s disease and other innate inflammatory diseases. Neurobiol Aging 2001;22:843–848.
  17. Querfurth HW, LaFerla FM: Alzheimer’s disease. N Engl J Med 2010;362:329–344.
  18. Benetti R, García-Cao M, Blasco MA: Telomere length regulates the epigenetic status of mammalian telomeres and subtelomeres. Nat Genet 2007;39:243–250.
  19. Cross S, Lindsey J, Fantes J, McKay S, McGill N, Cooke H: The structure of a subterminal repeated sequence present on many human chromosomes. Nucleic Acids Res 1990;18:6649–6657.
  20. Hansen RS, Wijmenga C, Luo P, et al: The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome. Proc Natl Acad Sci USA 1999;96:14412–14417.
  21. Yehezkel S, Segev Y, Viegas-Péquignot E, Skorecki K, Selig K: Hypomethylation of subtelomeric regions in ICF syndrome is associated with abnormally short telomeres and enhanced transcription from telomeric regions. Hum Mol Genet 2008;17:2776–2789.
  22. Maeda T, Guan JZ, Oyama J, Higuchi Y, Makino N: Aging-associated alteration of subtelomeric methylation in Parkinson’s disease. J Gerontol A Biol Sci Med Sci 2009;64:949–955.
  23. Maeda T, Guan JZ, Higuchi Y, Oyama J, Makino N: Aging-related alterations of subtelomeric methylation in sarcoidosis patients. J Gerontol A Biol Sci Med Sci 2009;64:752–760.
  24. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, 1994, pp 104–152.
  25. Ciabattoni G, Maclouf J, Catella F, FitzGerald GA, Patrono C: Radioimmunoassay of 11-dehydrothromboxane B2 in human plasma and urine. Biochim Biophys Acta 1987;918:293–297.
  26. Wang Z, Ciabattoni G, Créminon C, Lawson J, Fitzgerald GA, Patrono C, Maclouf J: Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. J Pharmacol Exp Ther 1995;275:94–100.
  27. Gerss J, Köpcke W: The questionable association of vitamin E supplementation and mortality–inconsistent results of different meta-analytic approaches. Cell Mol Biol (Noisy-le-grand) 2009;55(suppl):OL1111–OL1120.
  28. Devaraj S, Tang R, Adams-Huet B, Harris A, Seenivasan T, de Lemos JA, Jialal I: Effect of high-dose alpha-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease. Am J Clin Nutr 2007;86:1392–1398.
  29. Guan JZ, Maeda T, Sugano M, Oyama J, Higuchi Y, Suzuki T, Makino N: An analysis of telomere length in sarcoidosis. J Gerontol A Biol Sci Med Sci 2007;62:1199–1203.
  30. Guan JZ, Maeda T, Sugano M, Oyama J, Higuchi Y, Makino N: Change in the telomere length distribution with age in the Japanese population. Mol Cell Biochem 2007;304:353–360.
  31. Guan JZ, Maeda T, Sugano M, Oyama J, Higuchi Y, Suzuki T, Makino N: A percentage analysis of the telomere length in Parkinson’s disease patients. J Gerontol A Biol Sci Med Sci 2008;63:467–473.
  32. Maeda T, Guan JZ, Oyama J, Higuchi Y, Makino N: Age-related changes in subtelomeric methylation in the normal Japanese population. J Gerontol A Biol Sci Med Sci 2009;64:426–434.
  33. de Lange T, Shiue L, Myers RM, Cox DR, Naylor SL, Killery AM, Varmus HE: Structure and variability of human chromosome ends. Mol Cell Biol 1990;10:518–527.
  34. Hemann MT, Strong MA, Hao LY, Greider CW: The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell 2001;107:67–77.
  35. Cherif H, Tarry JL, Ozanne SE, Hales CN: Ageing and telomeres: a study into organ- and gender-specific telomere shortening. Nucl Acids Res 2003;31:1576–1583.
  36. Coyle JT, Puttfarcken P: Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993;262:689–695.
  37. Aksenov MY, Aksenova MV, Butterfield DA, Geddes JW, Markesbery WR: Protein oxidation in the brain in Alzheimer’s disease. Neuroscience 2001;103:373–383.
  38. Prasad KN, Cole WC, Hovland AR, Prasad KC, Nahreini P, Kumar B, Edwards-Prasad J, Andreatta CP: Multiple antioxidants in the prevention and treatment of neurodegenerative disease: analysis of biologic rationale. Curr Opin Neurol 1999;12:761–770.
  39. Rokach J, Khanapure SP, Hwang S-W, Adiyaman M, Lawson JA, FitzGerald GA: The isoprostanes: a perspective. Prostaglandins 1997;54:823–851.
  40. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G: Widespread peroxynitrite-mediated damage in Alzheimer’s disease. J Neurosci 1997;17:2653–2657.
  41. Montine TJ, Markesbery WR, Morrow JD, Roberts LJ 2nd: Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer’s disease. Ann Neurol 1998;44:410–413.
  42. Waddington E, Croft K, Clarnette R, Mori T, Martins R: Plasma F2-isoprostane levels are increased in Alzheimer’s disease: evidence of increased oxidative stress in vivo. Alzheimers’ Rep 1999;2:277–282.
  43. Pratico D, Clark CM, Lee VM, Trojanowski JQ, Rokach J, Fitzgerald GA: Increased 8,12-iso-iPF(2 alpha)-IV in Alzheimer’s disease: correlation of a specific noninvasive index of lipid peroxidation with disease severity. Ann Neurol 2000;48:809–812.
  44. Tuppo EE, Forman LJ, Spur BW, Chan-Ting RE, Chopra A, Cavalieri TA: Sign of lipid peroxidation as measured in the urine of patients with probable Alzheimer’s disease. Brain Res Bull 2001;54:565–568.
  45. Franco R, Schoneveld O, Georgakilas AG, Panayiotidis MI: Oxidative stress, DNA methylation and carcinogenesis. Cancer Lett 2008;266:6–11.
  46. Wachsman JT: DNA methylation and the association between genetic and epigenetic changes: relation to carcinogenesis. Mutat Res 1997;375:1–8.
  47. Weitzman SA, Turk PW, Milkowski DH, Kozlowski K: Free radical adducts induce alterations in DNA cytosine methylation. Proc Natl Acad Sci USA 1994;91:1261–1264.
  48. Turk PW, Laayoun A, Smith SS, Weitzman SA: DNA adduct 8-hydroxyl-2′-deoxyguanosine (8-hydroxyguanine) affects function of human DNA methyltransferase. Carcinogenesis 1995;16:1253–1255.
  49. Turk PW, Weitzman SA: Free radical DNA adduct 8-OH-deoxyguanosine affects activity of HPA II and MSP I restriction endonucleases. Free Radic Res 1995;23:255–258.
  50. Kuchino Y, Mori F, Kasai H, et al: Misreading of DNA templates containing 8-hydroxydeoxyguanosine at the modified base and at adjacent residues. Nature 1987;327:77–79.
  51. Hepburn PA, Margison GP, Tisdale MJ: Enzymatic methylation of cytosine in DNA is prevented by adjacent O6-methylguanine residues. J Biol Chem 1991;266:7985–7987.
  52. Tan N-W, Li BF: Interaction of oligonucleotides containing 6-O-methylguanine with human DNA (cytosine-5-)-methyltransferase. Biochemistry 1990;29:9234–9240.
  53. Xiao W, Samson L: In vivo evidence for endogenous DNA alkylation damage as a source of spontaneous mutation in eukaryotic cells. Proc Natl Acad Sci USA 1993;90:2117–2121.
  54. Bourdel-Marchasson I, Delmas-Beauvieux MC, Peuchant E, Richard-Harston S, Decamps A, Reignier B, Emeriau JP, Rainfray M: Antioxidant defences and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age Ageing 2001;30:235–241.
  55. Kontush A, Mann U, Arlt S, Ujeyl A, Lührs C, Müller-Thomsen T, Beisiegel U: Influence of vitamin E and C supplementation on lipoprotein oxidation in patients with Alzheimer’s disease. Free Radic Biol Med 2001; 31:345–354.
  56. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease: the Alzheimer’s Disease Cooperative Study. N Engl J Med 1997;336:1216–1222.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50